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Abstract: 
 
We previously discovered that phytonutrient genistein rapidly activates cAMP signaling in β-
cells and improves islet mass in diabetic mice. However, the mechanism underlying these actions 
of genistein is still unclear. Here, we show that pharmacological or molecular inhibition of Gαs 
blocked genistein-stimulated adenylate cyclase activity in plasma membrane and intracellular 
cAMP production in INS1 cells and islets. Further, genistein stimulation of cAMP generation 
was abolished in islets exposed to a specific GPR30 inhibitor G15 or islets from GPR30 deficient 
(GPR30−/−) mice. In vivo, dietary provision of genistein (0.5 g/kg diet) significantly mitigated 
streptozotocin-induced hyperglycemia in male WT mice, which was associated with improved 
blood insulin levels and pancreatic islet mass and survival, whereas these effects were absent in 
Gpr30−/− mice. Genistein treatment promoted survival of INS1 cells and human islets 
chronically exposed to palmitate and high glucose. At molecular level, genistein activated CREB 
phosphorylation and subsequently induced Bcl-2 expression, and knockdown of CREB 
diminished the protective effect of genistein on β-cells induced by lipoglucotoxicity. Finally, 
deletion of GPR30 in β-cells or islets ablated genistein-induced CREB phosphorylation and its 
cytoprotective effect. These findings demonstrate that genistein is a survival factor for β-cells via 
GPR30-initiated, Gαs-mediated activation of CREB. 
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Article: 
 
1. Introduction 
 
It is estimated that over 30.3 million or 9.4% of people in the United States presently suffer 
from diabetes, and 57 million people have prediabetes [1]. While the availability of novel drugs, 
techniques, and surgical intervention has improved the survival rate of individuals with diabetes, 
the prevalence of diabetes is still rising in the United States, with the number of people with 
diabetes projected to double by 2025 [2]. Type 2 diabetes (T2D) is a result of chronic insulin 
resistance and progressive loss of β-cell mass and function [3]. In experimental animals and 
humans, obesity is a leading pathogenic factor for developing insulin resistance, and insulin 
resistance will progress to T2D when β-cells are unable to secret adequate amount of insulin to 
compensate for decreased insulin sensitivity, which is largely due to insulin secretory 
dysfunction and significant loss of functional β-cells [4], [5]. Indeed, those individuals with T2D 
always manifest increased β-cell apoptosis and reduced β-cell mass [5], [6], [7]. 
Sustained hyperlipidemia and hyperglycemia in β-cells play an important role in contributing to 
β-cell apoptosis and dysfunction, thereby leading to the deterioration of glycemic control and the 
overt development of T2D [8], [9]. As such, the search for agents that promote β-cell survival 
may provide an effective strategy to prevent the onset of diabetes [10]. 
 
Genistein is a flavonoid compound present in legumes and Chinese herbal medicines Genista 
tinctoria Linn and Sophora subprostrala Chun. It is widely used as a dietary supplement in the 
US for various presumed health benefits [11], [12], [13]. Genistein has been previously 
investigated for its potential beneficial effects on cancer treatment, cognitive function, and 
cardiovascular and skeletal health, with a primary focus on exploring its potential hypolipidemic, 
antioxidative and estrogenic effects [11], [12], [13]. While studies on whether genistein alone has 
an effect on diabetes are limited, available data showed that administration of genistein-
containing soy products lowered plasma glucose in diabetic animals [14], [15] and in 
humans [16], [17]. Genistein has been reported to exhibit antioxidant activity [18], [19]. 
However, this effect of genistein is achieved only at concentrations ranging from 25 to 100 μM, 
which are well beyond those achievable through dietary ingestion of genistein supplement in 
both humans and rodents. Thus, the mechanism of genistein's action as a potential antidiabetic 
agent is still unknown. We recently observed for the first time that genistein at physiologically 
achievable concentrations (0.1–5 μM) activated cAMP signaling by inducing adenylate cyclase 
(AC) activity in β-cells and islets [20]. We further demonstrated that dietary intake of genistein 
preserved β-cell mass and mitigated diabetes in mice [21]. In the present study, we investigated 
whether genistein directly promotes β-cell survival and prevents diabetes by targeting the G-
protein-coupled receptor (GPCR)-mediated signaling pathway. 
 
2. Research design and methods 
 
2.1. Materials and reagents 
 
Cell culture medium, supplements, palmitate, fatty acid-free bovine serum albumin (BSA), H89, 
mellittin, and protease and phosphatase inhibitor cocktails were from Sigma (St. Louis, MO, 
USA); genistein (purity≥99.0%) was from LC Laboratories (Woburn, MA, USA); ICI 182,780 
(ICI), 17β-estradiol (E2) and G15 were from Tocris Biosciences (Bristol, UK); insulin ELISA 
kits were obtained from Crystal Chemical Inc. (Chicago, IL, USA); cell viability and caspase-3 
assay kits, pRL luciferase control vector and dual luciferase assay system were purchased from 
Promega (Madison, WI, USA); cyclic AMP EIA kits were from Cayman Chemical Company 
(Ann Arbor, MI, USA); terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) 
assay kits were from Trevigen Inc. (Gaithersburg, MD, USA); the active form of the caspase-3 
antibody was from BD Biosciences (San Jose, CA, USA); the rabbit polyclonal anti-insulin 
antibody was from Abcam (Cambridge, MA, USA); antibodies for phospho-CREB (ser133), 
CREB and β-actin were from Cell Signaling Technology (Beverly, MA, USA); nitrocellulose 
membranes and protein assay kits were from Bio-Rad (Hercules, CA, USA); CREB ShortCut 
siRNA, scramble sequence of siRNA and transfection reagents were from New England Biolabs 
(Ipswich, MA, USA); anti-GPR30, anti-Gαs, shGαs lentiviral particles and GPR30 siRNA (rats) 
were from Santa Cruz Biotechnology (Santa Cruz, CA, USA); a reporter plasmid containing a 
promoter region of the Bcl-2 gene linked to a firefly luciferase gene (Bcl-2-Luc) was a gift of Dr. 
Linda M. Boxer, Stanford University; a reporter plasmid containing multiple copies of a 
consensus cAMP responsive element (CRE)-binding sequence fused to a TATA-like promoter 
region upstream of the gene for firefly luciferase (CRE-luc) was from BD Clontech, CA, USA; 
the plasmid transfection reagent was from Invitrogen, CA, USA; the ImmPRESS anti-rabbit Ig 
(peroxidase) polymer detection kit, vector NovaRED peroxidase substrate and vector SG 
peroxidase substrate were from Vector Laboratories (Burlingame, CA, USA). Stock solutions of 
genistein and E2 at 20 mM dissolved in dimethyl sulfoxide (DMSO) were stored at −20°C. 
 
2.2. Cell and human islet culture 
 
INS1 cells (provided by Dr. Pierre Maechler, University of Geneva Medical School) were 
cultured as previously described [22]. Human islets were supplied through the Integrated Islet 
Distribution Program (City of Hope Medical Center, Duarte, CA, USA). The islet purity and 
viability were over 90%. The islets were maintained in CMRL-1066 medium containing 10% 
FBS. Palmitate was dissolved in medium containing 7% fatty acid-free BSA, sonicated and 
sterile-filtered (final fatty acid/BSA molar ratio=6.6) [23]. For control experiments, palmitate-
free BSA was prepared in the same way as stated above. For examining the effects of genistein 
on CREB phosphorylation, INS1 cells or islets were preincubated with Krebs Ringer bicarbonate 
buffer for 20 min followed by treatment with genistein or vehicle for 30 min. In some 
experiments, INS1 cells or islets were preincubated with estrogen (E2) receptor (ER) antagonist 
ICI 182,780 (ICI; 10 μM), PKA inhibitor H89 (10 μM), Gαs inhibitor mellittin (M; 5 μM), 
GPR30 antagonist G15 (5 μM) or vehicle (DMSO) for 30 min before addition of genistein. 
 
2.3. AC and intracellular cAMP measurements 
 
For measuring AC activity, the plasma membranes from INS1 cells were isolated by differential 
centrifugation [24]. The membranes were preincubated with GDPβS (100 μM), Gαs antibody 
(1:200), nonimmune IgG or vehicle for 30 min at 25°C, followed by addition of genistein (2.5 
μM), GLP-1 (20 nM), forskolin (5 μM) or vehicle for 10 min. AC activity was then measured by 
determining cAMP production as previously described [24]. For intracellular cAMP 
measurements, islets were treated with genistein (5 μM) for 20 min. Intracellular cAMP levels 
were measured by an EIA kit [20]. Data were normalized to the cellular protein concentration in 
the same samples. 
 
2.4. Immunoblot analysis 
 
Equal amounts of protein (50 μg) from cell extracts were subjected to immunoblot analysis as 
previously described [21]. Membranes were first probed with an antibody against Gαs, GPR30, 
Bcl-2 or phospho-CREB (p-CREB). The immunoreactive proteins were detected by 
chemiluminescence. Nitrocellulose membranes were then stripped and reprobed with antibodies 
against CREB or β-actin. The protein bands were digitally imaged for densitometric quantitation 
with Image Lab instrument(Bio-Rad). The expression of p-CREB and Bcl-2 was normalized to 
that of total CREB and β-actin, respectively, and expressed as a fold increase over the control. 
 
2.5. Transfection assays 
 
INS1 cells were grown in a 24-well plate until 50% confluence. To determine whether genistein 
activates cAMP-regulated transcription, cells were co-transfected with 0.25 μg CRE-Luc reporter 
plasmid and 5 ng pRL reporter control vector per well using Lipofectamine 2000 transfection 
reagent according to the manufacturer's protocol. To examine whether genistein enhances Bcl-2 
transcription, cells were co-transfected with 0.5 μg Bcl-2-Luc vector and 1 ng pRL reporter 
plasmid per well. After transfection, cells were incubated with complete RPMI1640 medium for 
24 h, and then treated with genistein or vehicle for 16 h for CRE-luc-transfected cells or 24 h for 
Bcl-2-luc-transfected cells. Luciferase activity normalized to pRL activity in the cell extracts was 
then determined with a dual luciferase reporter assay system. 
 
For knockdown of CREB, INS1 cells were transfected with a heterogeneous mixture of target-
specific CREB siRNA (50 nM) or corresponding amounts of scrambled siRNA using siRNA 
transfection reagents according to the manufacturers' protocols. After 48 h of transfection, cells 
were incubated with or without genistein for 30 min for immunoblot analysis of CREB protein 
expression, or incubated with palmitate (0.5 mM) and high glucose (HG, 20 mM) in the presence 
or absence of genistein (5 μM) for 72 h followed by apoptosis assays. To delete GPR30, INS1 
cells were transfected with 100 nM GPR30 siRNA or scrambled siRNA in serum- and antibiotic-
free media for 16 h using Lipofectamine 2000 transfection reagent. Cells were then cultured in 
complete DMEM for 24 h, followed by treatment with 5 μM genistein or vehicle. 
 
2.6. Cell apoptosis assays 
 
INS1 cells or islets were cultured in complete RPMI-1640 medium with or without 0.5 mM 
palmitate and HG in the absence or presence of genistein (0.1, 1 and 10 μM) for 72 h, with 
genistein-supplemented media replaced after 48 h. Cellular apoptosis was measured with a 
TUNEL-based quantitative apoptotic assay kit. For measuring cellular caspase-3 activity, cells or 
islets were cultured under the above glucolipotoxic condition with or without genistein for 48 h. 
The caspase-3 activity in the cell lysates was measured using an assay kit and normalized to the 
cellular protein concentration, measured with a Bio-Rad assay kit. 
 
2.7. Animals and treatments 
 
WT or Gpr30−/− mice (breeding colony provided by Dr. Deborah Clegg, UT Southwestern) 
were housed in a room maintained on a 12-h light/dark cycle under constant temperature (22°C–
25°C) with ad libitum access to food and water. Homozygosity was confirmed via quantitative 
RT-qPCR. When mice were 7 months old, WT and Gpr30−/− male mice were divided into four 
groups with their initial body weight and blood glucose balanced among groups. The mice were 
then fed a phytoestrogen-free high-fat diet (HFD, 45% kcal fat) or HFD supplemented with 
0.05% genistein. Body weight and food intake were recorded weekly. This genistein dosage was 
used (approximately a human intake of 25–200 mg/day) because it is within the range that 
humans can realistically consume through taking supplements [25]. After 4 weeks of treatment, 
mice were injected intraperitoneally streptozotocin (STZ) dissolved in 0.1 mM cold sodium 
citrate buffer (pH 4.5) at 40 mg/kg daily for 3 consecutive days. Control mice were injected the 
same amount of vehicle. After this procedure, mice remained on the same dietary treatment for 9 
weeks for the following metabolic measurements. Body weight and food intake were recorded 
weekly. The protocol of this study was approved by the Institutional Animal Care and Use 
Committee at Virginia Tech (protocol number: 11-176-HNFE). 
 
2.8. Metabolic measurements 
 
At the beginning of the experiment, fasting (12 h) blood glucose was measured in tail vein blood 
sample using a glucometer (Kroger). Following STZ injection, blood glucose was measured 
weekly to assess the onset of hyperglycemia (nonfasting blood glucose>250 mg/dl) [26]. Plasma 
insulin concentrations were measured by ELISA (Crystal Chem, IL, USA). Glucose tolerance 
and insulin sensitivity were assessed as previously described [21]. Fasting plasma total 
cholesterol and triacylglycerides were measured in triplicate using a Pointer 180 Analyzer 
(Pointe Scientific, Canton, MI, USA) as described [27]. 
 
2.9. Immunohistochemistry and islet morphometry 
 
At the end of the feeding study, mouse pancreata were collected and fixed as previously 
described [21]. A series of tissue sections (5-μm thickness) were prepared by AML Laboratory 
(Baltimore, MD) and immunostained to determine β-cell mass and apoptosis. The β-cell area was 
measured using images acquired from serial insulin-stained pancreatic sections (100-μm 
interval). The β-cell mass were calculated as previously described [21]. Apoptotic β-cells were 
detected by double labeling the sections with antibodies against activated caspase-3 and insulin 
using an ImmPRESS detection system as we previously described [28]. 
 
2.10. Statistical analysis 
 
Data were analyzed with one-way ANOVA using SigmaPlot software. Treatment differences 
were subjected to Tukey's test. A P value<.05 was considered significant. 
 
3. Results 
 
3.1. Genistein activation of cAMP signaling is mediated via Gαs in β-cells 
 
We recently found that genistein rapidly activates AC in β-cells [20]. AC activity is stimulated 
by G-protein α-subunit (Gαs), which is an important regulator of β-cell mass and function [29]. 
We found that genistein activation of AC in plasma membranes of β-cells was inhibited by 
GDPβS (Fig. 1A), which blocks the exchange of a GDP for a GTP and thereby inhibits the 
activation of G-proteins [30]. Further, preincubation of the plasma membranes from INS1 cells 
with anti-Gαs, which neutralizes and thereby blocks Gαs activation, ablated genistein activation 
of AC activity (Fig. 1B). Interestingly, genistein showed similar potency in inducing AC activity 
as glucagon-like-peptide-1 (GLP-1), a potent incretin that activates Gαs/AC signaling via its 
receptor β-cells. The effect of GDPβS or anti-Gαs on genistein-induced AC activation is specific 
because they did not influence forskolin-induced AC activity. 
 
 
Fig. 1. Genistein activated cAMP signaling via a Gαs-mediated mechanism in β-cells. (A) AC activity in INS1 cell 
plasma membranes preincubated with 100 μM GDPβS (A), Gαs antibody (Gαs, 1:200) (B), nonimmune IgG or 
vehicle (V) for 30 min at 25°C, followed by stimulation with genistein (G, 2.5 μM), GLP-1 (GLP, 20 nM), 
forskolin (Fsk, 5 μM) or vehicle for 10 min. Intracellular cAMP levels in INS1 cells (C) or human islets (D) 
pretreated with Gαs inhibitor mellittin (M, 5 μM) for 30 min, followed by stimulation with genistein (G, 5 μM) for 
20 min. Islets were infected with lentiviral particles containing Gαs shRNA (Gαsh) or control shRNA (Csh) at MOI 
of 150. Forty-eight hours later, control and infected islets were either lysed for measuring Gαs and β-actin protein 
expression to determine the efficiency of knockdown (E) or incubated with genistein (G, 5 μM) for 20 min to 
measure intracellular cAMP levels (F). Cyclic AMP levels were normalized to the protein contents and expressed as 
percentage of the control value. Data are mean±S.E.M. (n=4). *P<.05 vs. control. 
 
To examine whether Gαs also mediates genistein-stimulated cAMP production in β-cells and 
islets, INS1 cells or human islets were preincubated in the absence or presence of the Gαs 
inhibitor, mellittin (5 μM), for 30 min [31], followed by addition of genistein (5 μM) or vehicle 
for 20 min. Inhibition of Gαs with mellittin blocked genistein-stimulated cAMP production in 
INS1 cells (Fig. 1C) and human islet cells (Fig. 1D). We then utilized shRNA-expressing 
lentiviral particles to suppress Gαs expression in human islets in order to further investigate 
whether Gαs mediates genistein-stimulated cAMP production in pancreatic islets. Consistently, 
infection of human islets with an Gαs-specific shRNA-expressing lentivirus ablated the 
expression of Gαs protein (Fig. 1E) and subsequently diminished genistein-triggered cAMP 
production (Fig. 1F), whereas the scrambled shRNA did not affect Gαs protein expression and 
genistein/cAMP signaling in the islets. Combined, these results provide evidence that Gas is 
essential in mediating genistein/cAMP signaling in β-cells. 
 
3.2. Genistein acts through GPR30 
 
Activation of AC could be linked to Gαs-coupled receptors [32], and genistein may bind to 
GPR30, a membrane-associated GPCR, in cancer cells [33]. We thus reasoned that genistein 
activation of cAMP signaling may be mediated via this receptor. We first confirmed that GPR30 
protein is highly expressed in clonal rodent β-cells and human and mouse islets (Fig. 2A). 
Incubation of INS1 cells with G15, a specific GPR30 inhibitor, diminished genistein-stimulated 
cAMP production (Fig. 2B). Knockdown of Gpr30 with siRNA (Fig. 2C) greatly ablated 
genistein-stimulated cAMP production in INS1 cells, whereas scrambled siRNA had no such 
effect (Fig. 2D). Furthermore, genistein stimulated cAMP generation in isolated WT mouse 
islets, but this genistein action was absent in Gpr30−/− islets (Fig. 2E). The deletion of GPR30 in 
islets from Gpr30−/− mice was confirmed by Western blot analysis of GPR30 protein expression 
(Fig. 2F). 
 
3.3. The antidiabetic action of genistein in mice is mediated via GPR30 
 
We next investigated whether GPR30 mediates the antidiabetic effect of genistein in vivo. Before 
STZ injection, genistein had no effect on body weight gain, food intake or nonfasting blood 
glucose levels in both WT and Gpr30−/− mice (data not shown). As expected, STZ injection 
induced hyperglycemia in both WT and Gpr30−/− mice (Fig. 3A and B). We observed that WT 
diabetic mice fed a genistein-supplemented HFD had significantly lower blood glucose levels as 
compared to HFD-fed WT diabetic mice (Fig. 3A), suggesting that genistein mitigated STZ-
induced hyperglycemia. However, genistein failed to lower blood glucose levels in STZ-
induced Gpr30−/− diabetic mice (Fig. 3B). Fasting blood glucose levels were not greatly 
increased by STZ injection or significantly modulated by genistein treatment (data not shown), 
indicating that STZ-induced elevation of blood glucose in our models is mainly due to a 
destruction of pancreatic β-cells, leading to deficiency of glucose-stimulated insulin secretion. 
Consistently, genistein significantly improved glucose tolerance (Fig. 3C and D) and 
postprandial circulating insulin levels (Fig.3E) in WT mice but not in Gpr30−/− mice (data not 
shown). Genistein had no effects on plasma lipid profiles (data not shown) and whole 
body insulin sensitivity in both WT (Fig. 3F) and Gpr30−/− (data not shown) mice. 
 
 
Fig. 2. Genistein stimulation of cAMP production was mediated via GPR30 in β-cells. (A) Protein expression of 
GPR30 in insulin-secreting cells and islets as determined by Western blot (h = human, M = mouse). (B) Intracellular 
cAMP levels in INS1 cells preincubated with vehicle (V) or GPR30 antagonist G15 (5 μM) for 10 min before 
stimulation with genistein (G, 5 μM) for 20 min. (C) Knockdown of GPR30 protein expression in INS1 cells 
transfected with GPR30 siRNA (I) or scrambled siRNA (S). Images shown were from two independent transfection 
experiments. (D) Intracellular cAMP levels in GPR30 siRNA (I) or scrambled siRNA (S) transfected cells and 
exposed to 5 μM genistein or vehicle (V) for 20 min. (E) Intracellular cAMP levels in wild-type (WT) or GPR30−/− 
(KO) islets incubated with vehicle (V), genistein (G, 5 μM) or foskolin (F, 1 μM) for 20 min. (F) Western blot for 
GPR30 knockout in the islets. Cyclic AMP levels were normalized to the protein contents and expressed as 
percentage of the control value. *P<.05 (n=3–4±S.E.M.). 
 
 
 
Fig. 3. The antidiabetic effect of genistein in STZ-induced obese diabetic mice was GPR30 dependent. WT or 
GPR30−/− male mice were fed a standard cow diet (SD), a high-fat diet (HF) or HF supplemented with 0.05% 
genistein (HF + G) for 4 weeks. Mild hyperglycemia in HF-fed mice was then induced by injection of STZ. 
Nonfasting blood glucose levels in WT (A) and GPR30−/− (B) mice were measured at the indicated time points. Data 
of intraperitoneal glucose tolerance test (C) and area under the curve (AUC) were calculated using the trapezoidal 
rule (D) in WT mice. (E) Nonfasting plasma insulin levels in WT mice. (F) Insulin tolerance test in WT mice at 5 
weeks after the first STZ injection. (G) A set of representative micrographs of pancreatic sections stained with 
insulin antibody. (H) The β-cell mass determined as described in “Materials and methods.” (I) Pancreas insulin 
contents measured by ELISA. (J) Representative activated caspase-3 (red) and insulin (blue) double staining of 
pancreatic sections from WT mice. (K) Quantification of caspase-3-positive β-cells expressed as percentage of total 
insulin-stained cells. Four pancreatic sections from each mouse with six mice per group were evaluated. Data are 
shown as means±S.E. or mean±S.E.M. (n=6 mice/group). *P<.05. 
 
Next, we examined whether genistein treatment preserved β-cell mass in WT diabetic mice. STZ 
administration severely decreased β-cell mass and disrupted the islet architecture. However, 
genistein-treated diabetic mice had significantly more islet β-cell mass and improved islet 
structure (Fig. 3G and H) concomitant with greater insulin content in the pancreas (Fig. 3I) as 
compared to control diabetic mice. Consistently, genistein reduced islet β-cell apoptosis, as 
determined by double immunolabeling of insulin and the activated caspase-3 (Fig. 3J and K), a 
key protease involved in the terminal steps of cell apoptosis. These results suggest that genistein 
improvement of hyperglycemia in STZ-induced obese diabetic mice is primarily due to GPR30-
dependent protection of islet function. 
 
3.4. Genistein prevents apoptosis of INS1 cells and islets exposed to glucolipotoxicity 
 
To determine whether genistein directly promotes survival of β-cells, we first evaluated whether 
genistein protects INS1 cells exposed to excessive amounts of saturated fatty acids and glucose 
(glucolipotoxicity), which are believed to cause β-cell apoptosis and impair its function, thereby 
contributing to the pathogenesis of T2D [23]. Incubation of INS1 cells with palmitate (0.5 mM) 
and HG for 72 h significantly increased apoptosis. However, co-treatment with genistein dose-
dependently prevented cell apoptosis induced by chronic glucolipotoxicity (Fig. 4A), with 1 μM 
genistein exerting a significant effect. In parallel to decreased apoptosis, the cellular caspase-3 
activity was markedly increased in INS1 cells under glucolipotoxicity, which was significantly 
reduced by genistein treatment (Fig. 4B). In consistent with this cytoprotective effect in INS1 
cells, genistein treatment also promoted survival of mouse (Fig. 4C and D) and human (Fig. 4E 
and F) islets chronically exposed to palmitate (0.5 mM) and HG (20 mM). To test whether 
genistein modulates antiapoptotic Bcl-2 expression, which could be a mechanism through which 
genistein promotes islet cell survival, we incubated INS1 cells with genistein for 24 h and found 
that genistein greatly induced Bcl-2 protein expression (Fig. 4G), which was accompanied with 
increased Bcl-2 promoter activity (Fig. 4H) as determined by a reporter gene assay, suggesting 
that genistein may regulate Bcl-2 expression at the transcriptional level in β-cells. Collectively, 
these results demonstrate that genistein directly promotes islet β-cell survival. 
 
Fig. 4. Genistein protected INS1 cells and islets from apoptosis. INS1 cells (A, B), mouse (C, D) or human (E, F) 
islets were pretreated with or without genistein (G) at indicated concentrations for 12 h, followed by addition of 0.5 
mM palmitate (PA) and 20 mM glucose (Glu). Cellular apoptosis (A, C, E) and caspase-3 activity (B, D, F) were 
measured after 72 h and 48 h of treatment, respectively. Values were expressed as fold of the control. (G) INS1 cells 
were treated with genistein (G) or vehicle for 48 h. Cellular Bcl-2 protein was detected by Western blot and 
normalized to β-actin content. (H) INS1cells were co-transfected with Bcl-2 promoter and control plasmids, 
followed by addition of genistein for 24 h. Luciferase activity in the cell lysates was measured. *P<.05 vs. control; 
#P<.05 vs. Glu and PA-alone treated islets (n=4±S.E.M.). 
 
3.5. The antiapoptotic effect of genistein is independent of ER 
 
As genistein may have weak estrogenic effects on some tissues and previous studies showed that 
E2 can promote β-cell survival [34], [35], we examined whether genistein promotion of islet 
survival was mediated via ERs. Genistein or E2 alone reduced human islet cell apoptosis (Fig. 
5A). However, incubation of human islets with ICI182,780, a specific antagonist of ERα and 
ERβ, reduced the cytoprotective effect of E2 by 70% but had no effect on genistein-mediated 
action. Moreover, daidzein, an analogue of genistein that is essentially inactive as an ER 
ligand [36], also prevented β-cell apoptosis (Fig.5B). These results indicate that genistein actions 
in β-cells are likely independent of ERα- and ERβ-mediated signaling machinery. 
 
 
Fig. 5. The antiapoptotic effect of genistein was independent of ERα and ERβ. (A) Co-incubation of human islets 
with ER inhibitor ICI 182,780 (ICI, 10 μM) blocked the effect of 17β-estradiol (E2; 0.1 μM), but not that of 
genistein (Gen, 1 μM), on high-glucose- (Glu, 20 mM) and palmitate- (PA, 0.5 mM) induced islet apoptosis. (B) 
Genistein (G, 5 μM) and its nonestrogenic analog daidzein (D, 5 μM) protected human islets from high-glucose- 
(Glu; 20 mM) and palmitate- (PA; 0.5 mM) induced apoptosis. *P<.05 (n=4±S.E.M.). 
 
 
Fig. 6. The cytoprotecitve effect of genistein on β-cells was dependent of GPR30-mediated activation of CREB. 
Western blot analyses of phosphorylated (p-CREB) and total CREB in INS1 cells (A) or human islets (B) incubated 
with various concentrations of genistein or vehicle for 30 min. (C) Total CREB and p-CREB protein levels in INS1 
cells pretreated with PKA inhibitor H89 (10 μM) or vehicle (V) for 30 min, followed by addition of genistein (G, 5 
μM) for 30 min. (D) INS1 cells transfected with reporter plasmid pCRE-Luc were incubated with vehicle or 
genistein for 24 h. Luciferase activity was measured and normalized to the control plasmids in the cell extracts. (E) 
INS1 cells were transfected with vehicle (V), scrambled siRNA (S) or siRNA directed against CREB (I) for 48 h. 
The efficiency of knockdown in transfected cells was verified by immunoblot analysis of CREB protein levels. (F) 
Total and p-CREB levels in control or transfected INS1 cells treated with genistein (G, 5 μM) or vehicle (V) for 30 
min. (G) Bcl-2 protein levels in control or transfected INS1cells treated with genistein (G, 5 μM) or vehicle (V) for 
48 h. (H) Quantification of apoptosis in control or transfected INS1 cells following treatment with 0.5 mM palmitate 
(PA) and high glucose (Glu, 20 mM) or vehicle in the presence or absence of 5 μM genistein (G) for 72 h. (I) INS1 
cells were transfected with scrambled control siRNA (S) or GPR30 siRNA (I). Forty-eight hours later, genistein (5 
μM) effect on p-CREB and total CREB protein contents in cells were measured by Western blot. (J) total CREB and 
p-CREB levels in WT and GPR30−/− (KO) islets isolated from male mice and treated with or without genistein (G, 5 
μM) for 30 min. (K) Cellular caspase-3 activity in WT and KO islets incubated with palmitate (PA, 0.5 mM) plus 20 
mM glucose (Glu) in the presence or absence of genistein (G, 5 μM) for 24 h. Values are mean±S.E.M. (n=4). 
*P<.05. 
 
3.6. The cytoprotective effect of genistein in β-cells depends on GPR30-mediated activation of 
CREB 
 
To investigate the underlying mechanism through which genistein promotes β-cell survival, we 
first determined whether genistein treatment activates CREB, an important β-cell survival 
factor [37]. Exposure of INS1 cells (Fig. 6A) and human islets (Fig. 6B) to genistein for 30 min 
activated CREB, a pattern that is consistent with its effects on cAMP production and cell 
survival. Pretreatment of cells with PKA inhibitor H89 abolished genistein-induced CREB 
phosphorylation (Fig. 6C), suggesting that PKA mediates the genistein-stimulated 
phosphorylation of CREB. We then tested whether the activation of CREB by genistein is 
sufficient to affect transcription of cAMP-regulated genes, which include Bcl-2. Genistein at as 
low as 1-μM concentration significantly stimulated CRE-mediated luciferase activity in INS1 
cells, with 10-μM dose inducing a more than 1.5-fold increase in transcription over the control 
(Fig. 6D). Next, we used RNA interference to examine whether genistein protection of β-cell 
apoptosis is mediated via activation of CREB. Transfection of β-cells with CREB-specific 
siRNA greatly reduced CREB protein expression, whereas the scrambled siRNA did not affect 
CREB expression (Fig. 6E). Accordingly, disruption of CREB expression with siRNA 
diminished genistein-induced CREB phosphorylation (Fig. 6F), Bcl-2 protein expression (Fig. 
6G) and its cytoprotective effect (Fig. 6H) in INS1 cells, whereas transfection with a scrambled 
siRNA had no effect on genistein-mediated actions. To further investigate whether genistein 
activation of CREB is mediated via GPR30, we transfected INS1 cells with siRNA of GPR30 or 
its scrambled control. Knockdown of GPR30 mRNA, which greatly reduced its protein 
expression (Fig. 2C), ablated genistein-stimulated CREB phosphorylation without affecting total 
CREB expression in INS1 cells (Fig. 6I). Similarly, genistein stimulated CREB phosphorylation 
(Fig. 6J) and protected against apoptosis (Fig. 6K) of WT islets exposed to palmitate and HG, but 
these effects were absent in Gpr30−/− islets. Collectively, these data for the first time 
demonstrated that genistein prevents β-cells from apoptosis via GPR30-mediated activation of 
CREB. 
 
4. Discussion 
 
It has been shown that administration of phytonutrient genistein lowered plasma glucose in 
diabetic animals [14], [15] and in humans [16], [17] without affecting insulin sensitivity and fat 
metabolism. However, the molecular mechanism of this genistein action is still unclear. In the 
present study, we provide evidence for the first time that genistein directly promotes β-cell 
survival via the GPR30/Gα/AC/cAMP/PKA/CREB signaling pathway. Notably, this finding is 
physiologically relevant, as the effective doses of genistein (1–10 μM) overlap with those 
achievable by dietary intake of genistein supplement, which can achieve the total plasma 
genistein levels in the range of 1–7 μM in rodents and humans [13]. Consistent with these ex 
vivo findings, we further demonstrated that oral administration of genistein at a dose that humans 
can take as dietary supplement [25] significantly mitigated hyperglycemia and preserved 
pancreatic β-cell mass in HFD- and STZ-induced obese diabetic mice, an effect that was 
abolished in GPR30−/− mice. The significance of our findings is that they establish a 
mechanistic basis for the physiological actions of genistein. As the loss of functional β-cell mass 
plays a central role in the deterioration of blood glucose control in both T1D and T2D [5], the 
search for agents that promote β-cell survival and thereby preserve functional β-cell mass may 
provide an effective strategy to prevent the onset of diabetes. In this regard, genistein may be a 
safe and low-cost novel natural compound that can be used to prevent or ameliorate diabetes. 
 
We recently discovered that genistein is a potent activator of cAMP signaling in islet β-
cells [20]. However, the underlying mechanism of this genistein effect is unclear. In the present 
study, we performed a series of complementary experiments with the results indicating that Gαs 
activation is the upstream of the genistein-elicited cAMP signaling in β-cells. As genistein 
activates AC via Gαs in plasma membranes of β-cells, and cell membrane-associated G-proteins 
are typically activated by GPCRs, we speculated that this genistein action is transmitted via a 
membrane-bound receptor, which subsequently activates intracellular signaling in β-cells. 
Genistein is known to have an affinity for ERα and ERβ, although it is unclear whether the 
physiological effects of genistein observed in vivo are mediated by these classical ERs. Recent in 
vitro studies provide evidence that plasma membrane-associated GPR30 and ER36α, a 36-kDa 
variant of ERα, are novel membrane ERs that mediate the membrane-initiated E2 signaling in 
cancer cells [38], [39]. We chose to study GPR30 as we showed that it is highly expressed in 
islets and β-cells consistent with recent observations [35], [40], whereas ER36α is not detectable. 
Incubation of β-cells with G15, a selective GPR30 antagonist that do not interfere with the 
classical nuclear ER signaling [41], abolished genistein-stimulated cAMP production. In 
accordance with this result, knockdown of GPR30 with siRNA in β-cells or deletion of Gpr30 in 
mouse islets greatly reduced genistein-stimulated intracellular cAMP production. These data for 
the first time, to our knowledge, demonstrated that genistein may act on the cell membrane, 
eliciting a GPR30-mediated action that leads to the activation of cAMP signaling in β-cells. 
 
Intriguingly, GPR30 is expressed not only in the plasma membrane but also in the endoplasmic 
reticulum and the Golgi complex [42], [43], [44], [45], [46], [47], [48], suggesting that GPR30 is 
an atypical GPCR. Thus, it is possible that GPR30 is activated intracellularly by genistein and 
then translocates to the cell membranes to initiate cellular signaling [45], [46]. While it is still 
unclear how GPR30 exactly interacts with the receptor ligands, which is largely due to the 
challenge in purifying active protein from the membrane, it appears that GPR30 can be activated 
by structurally diverse molecules such as E2, G1 and ER antagonist tamoxifen and 
fulvestrant [49], suggesting that it has large plasticity in accepting ligands. Interestingly, our 
unpublished data show that a large group of structurally related flavonoids also potently activates 
cAMP-mediated signaling. It may thus be speculated that GPR30 is a common target for 
flavonoids, confirmation of which could provide novel insights regarding the physiological roles 
of many flavonoids that are ubiquitous in the human diet. 
 
We further investigated whether GPR30 mediates the antidiabetic action of genistein using WT 
and Gpr30−/− mice. In that regard, we used STZ to induce diabetes by directly causing the 
destruction of β-cells. We show that oral administration of genistein (50 mg/kg/d) significantly 
ameliorated hyperglycemia and glucose intolerance in WT obese diabetic mice, but these 
protective effects of genistein were completely absent in Gpr30−/− mice. The antidiabetic effect 
of genistein observed in this study might be relevant to humans because this dose of genistein 
used in the present study (equivalent to the human intake of 75–100 mg/day) is within the dose 
range typically consumed by humans [50]. In addition, we chose to examine genistein effect in 
older adult mice (7 months) because T2D usually occurs at middle and older age in humans. The 
diabetic mouse models used in this study were generated by HFD feeding and three mild doses 
of STZ administration that did not cause diabetes in chow-fed mice as we previously 
determined [51]. This mouse model shares the metabolic characteristics of human T2D with 
peripheral insulin resistance and reduced β-cell mass and function. In the present study, we 
observed that genistein had no effect on fasting blood glucose, which is primarily derived from 
hepatic glucose production [52], suggesting that gluconeogenesis was not altered by genistein. In 
line with our recent finding [21], genistein did not alter body weight gain, food intake, fat mass, 
plasma lipid profile, or insulin sensitivity, indicating that the blood glucose-lowering effect of 
genistein is not a secondary action whereby genistein modulated these variables. In contrast, 
genistein treatment significantly improved nonfasting plasma insulin levels in WT diabetic mice. 
These results suggest that the improvements in glycemic control by genistein treatment are 
primarily due to the improved pancreatic β-cell function, given that STZ induces diabetes by 
directly causing β-cell destruction and insulin deficiency. Consistently, dietary supplementation 
of genistein to WT mice partially prevented β-cell apoptosis and preserved islet mass 
concomitant with higher pancreas insulin content. 
 
The present study showed that genistein directly promotes β-cell and islet survival. While 
genistein can bind to the ERs, and it was reported that E2 can protect islets against stimuli-
induced apoptosis via the ER-dependent mechanisms [35], the protective effect of genistein 
against glucolipotoxicity-induced apoptosis in β-cells was not dependent on the ER-mediated 
pathway. First, ICI, a highly specific ER inhibitor, blocked E2 effect but did not affect the 
cytoprotective effect of genistein in β-cells. In addition, daidzein, an analogue of genistein that is 
essentially inactive as an ER ligand [36], also prevented β-cell apoptosis. Moreover, genistein 
primarily binds to ERβ but not ERα [36], and a recent study indicates that E2 acts primarily 
through ERα to protect β-cells from apoptosis [35]. Indeed, ERα expression level in the islets is 
10-fold higher than that of ERβ [40]. These results further imply that genistein may prefer to 
activate GPR30 in β-cells, while E2 uses ERα to promote cell survival when all three receptors 
are present. 
 
We further revealed that genistein prevents islets from apoptosis via GPR30-mediated activation 
of cAMP/PKA/CREB signaling. Our data showed that genistein strongly induced PKA-
dependent, rapid phosphorylation of CREB in INS1 cells and islets, which was associated with 
the induction of the expression of the antiapoptotic Bcl-2 protein. Further, we demonstrated that 
Bcl-2 is a downstream effector of CREB in the genistein-triggered signaling cascade and cell 
survival because knockdown of CREB diminished genistein-induced Bcl-2 protein expression 
and islet cell survival, indicating that CREB-mediated up-regulation of Bcl-2 protein expression 
plays a major role in genistein promotion of β-cell survival. It is conceivable that genistein 
regulates Bcl-2 at the transcriptional levels given that the CRE site present within Bcl-2 promoter 
plays a major role in inducing its expression [53]. Indeed, we found that genistein stimulated 
both cAMP-regulated gene expression and Bcl-2 promoter activity in β-cells. Finally, 
knockdown or deletion of GPR30 abolished genistein-stimulated CREB phosphorylation in β-
cells, supporting that genistein acts on GPR30 to initiate the antiapoptotic signaling in β-cells. 
 
In summary, we provide both in vitro and in vivo evidence for the first time that genistein 
stimulates cAMP signaling via a GPR30-mediated mechanism in β-cells, leading to improved 
islet survival. Loss of functional β-cell mass is the key for the deterioration of glycemic control 
in both T1D and T2D. In this context, genistein could be a naturally occurring agent that can be 
used as an alternative or complementary treatment for diabetes. 
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